→ Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the business will launch under the name Idorsia. When the deal was originally announced, Clozel had pencilled in NewCo for his next venture.
→ Aurinia $AUPH took advantage of a rising share price to round up $150 million in a new offering. But the stock took a beating Tuesday after the biotech decided to offer the shares at a deep discount.
→ New GSK CEO Emma Walmsley won’t be paid as well as her predecessor, Andrew Witty. The pharma giant overall is cutting the pay packet by 25% for Walmsley, who is stepping up to her first job as CEO. The company performed a review of its pay practices, aware of some criticism it’s been getting as generic Advair makes its way to the market.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.